With results that compare well with existing clinical methods, this study demonstrates the value of using motion sensor technology, available in most commercial smartphones today, for the detection of clinical heart failure. The multi-site study was conducted at three hospitals, including Stanford University Hospital, Turku University Hospital, and Helsinki University Hospital.

The study of >1000 patients reached its primary endpoint of recognizing clinical heart failure with smartphone-based technology. Comprehensive results of the study will be published later in 2022.

EU funding will accelerate the development and global market entry preparation of the CardioSignal by Precordior® product family to include detection of Heart Failure and Coronary Artery Disease with built-in smartphone motion sensors, the new revolutionary smartphone-only technology.